Praxis Precision Medicines (PRAX) Cash from Financing Activities (2019 - 2026)

Praxis Precision Medicines' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $609.4 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 1022.98% year-over-year to $609.4 million in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 225.87% increase from a year earlier, with the FY2025 full-year figure at $702.2 million, up 36.52% from the prior year.
• Cash from Financing Activities slipped to $609.4 million in Q1 2026 per PRAX's latest filing, from $612.5 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $612.5 million in Q4 2025 and bottomed at $504000.0 in Q2 2022.
• The 5-year median for Cash from Financing Activities is $23.3 million (2023), against an average of $120.5 million.
• Across the five-year window, Cash from Financing Activities tumbled 99.49% in 2022 and surged 13724.4% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at $5.4 million in 2022, then retreated by 23.41% to $4.1 million in 2023, then jumped by 2657.32% to $113.8 million in 2024, then surged by 438.4% to $612.5 million in 2025, then fell by 0.5% to $609.4 million in 2026.
• Per Business Quant, the three latest PRAX Cash from Financing Activities figures stand at $609.4 million (Q1 2026), $612.5 million (Q4 2025), and $6.8 million (Q3 2025).